Par subsidiary updates two products in pipeline

WOODCLIFF LAKE, N.J. A subsidiary of Par Pharmaceutical Cos. has announced an update on two products in its pipeline.

Strativa Pharmaceuticals said Thursday that it submitted a regulatory approval application for its orally dissolving film strips formulation of ondansetron to the Food and Drug Administration. The company is seeking approval of the drug in the 4-mg and 8-mg strengths for prevention of vomiting resulting from chemotherapy, radiation therapy and surgery. The drug’s active ingredient is the same as the one in GlaxoSmithKline’s Zofran ODT.

At the same time, the FDA rejected an application from Strativa development partner BioAlliance Pharma for the drug Loramyc (miconazole) mucoadhesive buccal tablet, a treatment for thrush.